Breast Cancer Molecular Subtypes and Skeletal Metastases Patterns on Bone Scintigraphy | NCT07750340

NCT07750340

Overview

NCT ID: NCT07750340
Lead Sponsor: Sohag UniversityOTHER
Official Title: Association of Breast Cancer Molecular Subtypes With Patterns of Skeletal Metastases on Bone Scintigraphy
Brief Summary: The goal of this observational study is to evaluate the association between different molecular subtypes of breast cancer and their specific patterns of skeletal metastases on Technetium-99m MDP bone scintigraphy.

The study will include adult male and female patients aged 18 to 80 years with histopathologically confirmed breast cancer who are referred for whole-body bone scintigraphy.

The main questions it aims to answer are:

What is the frequency and pattern of skeletal metastases across different breast cancer molecular subtypes (Luminal A, Luminal B, HER2-enriched, and Triple-Negative) on bone scintigraphy?

How do nuclear medicine scintigraphic findings correlate with tumor biomarker profiles? Researchers will compare imaging patterns among the different molecular subtype groups to determine if specific biomarker profiles correlate with distinct bone metastatic behaviors.
Conditions

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: No
Eligibility Criteria: Inclusion Criteria:

Patients of both sexes (females and males) with a confirmed histopathological diagnosis of breast cancer, including all major histological types: Invasive Ductal Carcinoma (IDC), Invasive Lobular Carcinoma (ILC), other mixed or less common epithelial variants.

Patient's age ranging from 18 to 80 years.

Available immunohistochemical (IHC) profiles from the primary breast tumor biopsy or surgery, covering all molecular subtypes including; Luminal A: (ER-positive, PR-positive, HER2-negative, and low Ki-67 index). Luminal B: (ER-positive, PR-variable, HER2-variable "either positive or negative", and high Ki-67 index). HER2-enriched: (ER-negative, PR-negative, and HER2-positive). Triple-Negative breast cancer (TNBC): (no ER, PR or HER2 expression).

Patients referred for bone scintigraphy as part of initial staging, follow-up, or due to clinical suspicion of bone metastasis.

Exclusion Criteria:

Patients with other primary malignancies (to avoid confusion regarding the origin of bone metastases).

Patients with incomplete medical records or unavailable immunohistochemical data.

Pregnant female patients.

Patients aged under 18 years old.

NCT00420433Completed

Bone Response in Metastatic Breast Cancer Involving Bones

NCT00682253Unknown status

Use of Bone Scintigraphy, CT and MRI in Breast Cancer

NCT07248033Not yet recruiting

Role of SPECT/CT of Bone Scan in Charactarization of Bone Lesions

NCT02900118Completed

Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis (EMOS)

NCT01339780Completed

Imaging of Prostate and Breast Cancer Bone Metastases Using Magnetic Resonance Imaging and Nuclear Medicine Techniques

NCT01224873Unknown status

Diagnosis of Bone Metastases in Breast Cancer: Bone Scintigraphy, Fluoride-PET and FDG-PET

NCT02109952Unknown status

Biomechanics of Metastatic Defects in Bone

NCT04159376Unknown status

Assessment of the Accuracy of PET/MR in Detection and Monitoring Response of Bone Metastases